
-
Mersana Therapeutics NasdaqGS:MRSN Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Location: 840 Memorial Drive, Cambridge, MA, 02139, United States | Website: https://www.mersana.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-34.17M
Cash
102.3M
Avg Qtr Burn
-19.75M
Short % of Float
13.62%
Insider Ownership
1.48%
Institutional Own.
72.28%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Emiltatug Ledadotin (Emi-Le; XMT-1660) Details Ovarian cancer, Breast cancer, Endometrial cancer | Phase 1 Data readout | |
XMT-2056 (HER2 ADC) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
XMT-1592 (NaPi2b antigen) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Failed Discontinued |